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Abstract
Dynamic interactions between CD4+ T cells and B cells are needed for humoral immunity and
CD4+ T cell memory. It is not known whether B cells are needed early on to induce the formation
of memory precursor cells or are needed later to sustain memory cells. Herein, primary and
memory CD4+ T cells responses were followed in wildtype mice that were depleted of mature B
cells by anti-CD20 before or different times after acute lymphocytic choriomeningitis virus
(LCMV) infection. The antibody treatment led to a 1000-fold reduction in B cell number that
lasted 6 weeks. Primary virus-specific CD4+ Th1 cells were generated in B cell-depleted mice,
however, there was a decrease in the CD4+Ly6CloTbet+ memory precursor population and a
corresponding 4-fold reduction in CD4+ memory cell number. Memory T cells showed impaired
cytokine production when they formed without B cells. B cell-depletion had no effect on
established memory populations. During disseminating virus infection, B cell depletion led to
sustained weight loss, functional exhaustion of CD4+ and CD8+ T cells, and prevented mice from
resolving the infection. Thus, B cells contribute to the establishment and survival of memory
CD4+ T cells following acute infection and play an essential role in immune protection against
disseminating virus infection.
Introduction
Millions of patients are treated with drugs to deplete autoreactive B cells. In rare instances,
there is an association between the loss of B cells and reduced immunity against pathogens
(1, 2). B cell depletion (such as by anti-CD20; eg Rituximab) is a successful therapy for
treating rheumatoid arthritis and non-Hodgkin’s lymphoma (3, 4), yet it compromises T cell
immunity and increases susceptibility to opportunistic infections (1, 2). While some
evidence indicates that B cell depletion therapies have minimal effects on patient disease
course & infections (5, 6) other data indicate that B cell-depletion in increases the risk for
progressive multifocal leukoencephalopathy, which is caused by re-activation of a common
latent polyoma virus infection, the return of active hepatitis B virus infection, as well as
other serious systemic infections, and potentially impaired vaccine-induced T cell responses
(1, 2, 7, 8).
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Previously, we showed that congenitally B cell-deficient mice (μMT−/−) generate primary T
cell responses to acute LCMV infection; however, those mice have a selective defect in
CD4+ T cell memory (9). CD4+ T cells play a central role as the immune system confronts
infection (10). Their frequency correlates with vaccine-induced protection in people:
individuals with deficiencies in CD4+ T cell memory are not protected well by vaccines, are
susceptible to opportunistic infections, and have recurring reactivation of latent virus
infections. Antigen-specific CD4+ T cells promote vigorous humoral and cellular responses
that protect against pathogens, including recall CTL responses that are protective against re-
infection (11–14) and act during the memory phase to maintain and/or improve CD8
memory (15). Virus-specific CD4 T cells interactions actively sustain CD8 responses during
persistent virus infection (16–21) in part by producing IL-21 (22–24). Memory CD4+ T
cells can directly suppress infection due to their rapid production of IFNγ (25), directly kill
MHCII+ target cells (26), and enhance innate responses (27). Our previous analyses showed
that B cell-deficient μMT−/− mice are unable to resolve disseminating virus infections due
to defects in cellular immunity (9).
B cells contribute to T cell responses in ways that are independent of antibody production
(9, 28, 29). B cells express MHC-II, co-stimulatory molecules, lymphotoxin, TNF, and
OX40L and other cytokines, to interact with and activate antigen-specific CD4+ T cells,
influencing their differentiation into effector cells or memory (30–41). B cells stimulate
memory CD4+ T cell differentiation and promote TFH cell differentiation in infection and
vaccination models (42–50). In other circumstances, unique regulatory signals may be
communicated by B cells to T cells after infection or vaccination (51–53). B cells also
contribute to lymphoid organogenesis, and mice that are congenitally deficient in B cells
show profound defects in spleen organization and cellularity that may affect T cell
responses. During development, B cells produce lymphotoxin and TNF to differentiate B
cell and T cell zones that draw emigrants from the thymus. In this capacity, B cells are
involved in normal T cell-B cell segregation and microstructure of the spleen and populating
the spleen with other cell types (follicular dendritic cells, fibroblastic reticular endothelial
cells, marginal zone populations, dendritic cells). Thus, congenital absence of B cells
reduces the frequency other cell types, including dendritic cells and phagocytic macrophage
populations (54) that produce sustained interferon responses (55), and the number of mature
naïve T cells that are available in this organ to mount adaptive T cell responses. Finally, B
cells can directly limit virus infection, for example, by expressing LTb to stimulate marginal
zone macrophage type-1 interferon expression to limit the spread of VSV into neurons (56,
57).
It is not known whether B cells program early memory cell precursors, affect the
establishment of memory levels, or act during the maintenance phase to regulate memory
CD4 cell number. Moreover, it is unknown whether the effect of B cells on CD4+ T cell
memory is mediated by direct B cell interaction, B cell cytokine production, or B cell-
dependent lymphoid organ structure. Herein, we sought to better understand the role of B
cells at different stages of the T cell response after acute virus infection by transiently
depleting B cells early on or during established memory in immune mice. Using this
approach, the effect of B cells on CD4+ T cell memory and immune protection could be
disentangled from the effects of B cells on lymphoid architecture. We found that the
depletion of B cells during the expansion and contraction phases reduced the number of
memory cell precursors and the number and function of memory CD4+ T cells, but these
effects were not as severe as observed in μMT−/− mice. B cell depletion in immune mice
resulted in no apparent loss of CD4 memory cells, indicating that established memory CD4+
T cell populations are not linked to B cells. Finally, we show that B cell depletion had a
profound detrimental effect on the immune response to persisting virus infection,
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We used C57BL/6 mice, SMARTA TCR-transgenic mice specific for the I-Ab LCMV
epitope GP61-80 (58) and μMT−/− (B cell-deficient) mice (59). Adult mice (8–10 weeks old)
were infected by i.p. administration of 2 × 105 plaque forming units of LCMV (Armstrong
strain). Some mice were given an intravenous injection of 2×106 PFU of LCMV-Armstrong,
LCMV-t1b, or LCMV-A22 for re-challenge experiments. All mouse experiments were
approved by the University of North Carolina Hill Institutional Animal Care and Use
Committee. Viral stocks of plaque-purified LCMV were prepared from infected BHK-21
monolayers.
Anti-CD20 mAbs
We received anti-CD20 mAbs (aCD20: clone 5D2) from Genentech. Mice were given one
or two doses of anti-CD20 (200 μg/mouse in 100μl volume, i.p.) or same amount of isotype
control antibody (IgG2a, anti-KLH) diluted in phosphate buffered saline.
Flow cytometry
Single-cell suspensions of splenocytes were surface stained with combinations of
fluorescently labeled monoclonal antibodies that were specific for CD4 (clone RM4-5), CD8
(53–6.7), CD19 (6D5), B220 (RA3-6B2), CD11a (M17/4), KLRG1 (2F1/KLRG1), CD127
(A7R34), Thy1.1 (HIS51), CCR7 (4B12), ICOS (7E.17G9), CD20 (AISB12), MHC II
(M5/114/15/2), F4/80 (BM8), and Ly6c (HK1.4). CXCR5 was detected through a 3-step
staining protocol (45) using purified rat anti-CXCR5 (clone2G8), biotin-anti-rat IgG
(polyclonal sera), then streptavidin-allophycocyanin (Invitrogen). Monomers or
Streptavidin-APC-conjugated tetramers (DbGP33-41 and I-AbGP67) were provided by the
NIH Tetramer core facility at Emory University. The intracellular staining (ICCS) assay was
performed by culturing splenocytes with or without LCMV peptide in the presence of
brefeldin A. After 5 h of incubation, cells were stained for surface markers, washed, fixed
with formaldehyde, then permeabilized and exposed to mAbs specific for IFN-γ (XMG1.2),
IL-2 (JES6-5H4), T-bet (4B10), and TNF (MP6-XT22). Antibody stained cells were
detected by a FACSCalibur cytometer (BD Biosciences) and the data were analyzed with
FlowJo software (Tree Star). All listed mAbs above were purchased from Biolegend, except
for CXCR5 (BD Biosciences) and CD11a (eBioscience).
ELISAs
Serum IFN-α was quantified by VeriKine Mouse Interferon-Alpha ELISA Kit (PBL,
Piscataway, NJ) according to manufacturer’s instructions. LCMV-specific serum antibody
was quantified by using ELISA plates (Greiner bio-one, Monroe, NC) that were coated with
lysates from LCMV-infected BHK cells as described previously (60).
Statistics
Statistical analyses and graphing were done with Prism software (www.graphpad.com). An
unpaired two-tailed Student’s t-test was employed to evaluate the significance of differences
between groups.
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SMARTA CD4+ T cells fail to establish a memory population in μMT−/− mice
Our earlier analyses showed that endogenous CD4+ T cells in μMT−/− mice respond to
LCMV infection but fail to establish memory cells that make cytokine (9). The μMT−/−
mice have smaller spleens than WT mice before infection, so it is plausible that the
repertoire of virus-reactive CD4+ T cells in these mice does not include subpopulations of
effector cells that are capable of further differentiation into memory. A limitation with the
earlier analyses was that the detection of virus-specific T cells was based on a functional
readout (eg, ICCS), thus it is plausible that virus-specific memory CD4+ T cells were
present in immune μMT−/− mice but were unable to produce cytokine. To better understand
the underlying CD4+ T cell defects in these mice and circumvent these concerns, we utilized
an adoptive transfer model where a small number of SMARTA CD4+ T cells, which express
a TCR-transgene specific for LCMV-GP61-80 in I-Ab, were adoptively transferred into either
WT or μMT−/− mice followed by LCMV-Armstrong infection. In this experimental setup,
the differentiation process of the same population of T cells is examined in mice with B cells
or with no B cells. Additionally, the differentiating cells can be identified due to their
surface expression of congenic markers (Ly5a or Thy1.1) and quantified by direct surface
staining, independent of their production of cytokine.
At day 8, the primary CD4+ T cell response was vigorous in both groups of mice (Fig. 1A),
consistent with our earlier analyses of the endogenous response (9), and the mice resolved
the infection in the liver, lung, and kidney as measured by plaque assay (data not shown).
We observed that the majority of SMARTA CD4+ T cells made IFNγ, TNF, and IL-2 in
both hosts, but there was no significant difference in the percentage of SMARTA cells co-
expressing IFNγ with IL-2 (Fig. 1B and Fig. 4D). Interestingly, the amount of IFNγ and
IL-2 made per cell, as revealed by gMFI of cytokine staining, was greater for SMARTA
CD4+ T cells in the μMT−/− mice than in the WT mice (Supplemental Figure 1B). Thus, the
expansion of SMARTA CD4+ T cells is largely normal, but the cytokine output of
SMARTA CD4+ T cells is increased when the cells differentiate in the absence of B cells.
The T cell response was examined at day 44, which is during the memory phase. The
memory SMARTA CD4+ T cells represented ~0.3% of splenocytes in the WT mice;
however, SMARTA CD4+ T cells were near the limits of detection in the μMT−/− mice
(Fig. 1C). These frequencies corresponded to approximately 6×104 memory SMARTA
CD4+ T cells in WT mice and ~300 memory SMARTA CD4+ T cells in the μMT−/− mice
(Fig. 1D). Thus, there was a 220-fold reduction in memory in the μMT−/− mice. The defect
was specific for CD4+ T cells, since the memory CD8+ T cell response in the μMT−/− mice
appeared normal (data not shown and (9, 61)). These data indicate that the loss of CD4
memory in immune μMT−/− mice is due to the physical absence of memory cells rather than
the persistence of functionally impaired CD4 memory cells.
The above data show that the same cells undergo different fates depending on the recipient
mouse. Memory cell differentiation begins early on with a subset of effector cells (memory
precursor cells) transiting into the memory pool (62). The loss of CD4 memory in the B cell-
deficient mice could represent a defect in the formation of memory precursor cells among
the effector cells, or it could be that the mice generate memory precursor cells but fail to
sustain them during the contraction or memory phases. Thus, we wished to determine
whether the defect in memory was intrinsic to the T cells by day 8 or if it was related to the
B-less host environment. To address these two possibilities, we engrafted SMARTA cells
into WT or μMT−/− mice followed by LCMV-Armstrong infection to induce effector T
cells, including memory precursors. At day 8, the reactive SMARTA CD4+ cells were
isolated from the 2 groups of mice, mixed in equal proportion, and then transferred to the
Misumi and Whitmire Page 4













same infection-matched WT hosts (Fig. 2A). In this experimental setup, the early
differentiation steps of CD4+ T cells occurred in the presence or absence of B cells, but the
subsequent survival of the CD4+ T cells could be compared in the same host. After another
32 days, which is sufficient for the donor cells to transit into memory, the mice were either
left unchallenged to evaluate the establishment/maintenance of memory cells under
homeostatic conditions or challenged with high-dose LCMV-Armstrong to evaluate the
recall response of the donor memory cells. The effector CD4+ T cells from the μMT−/−
mice and WT mice established comparable levels of memory when transferred into WT
mice (Fig. 2B, left, white bars). Thus, the effector CD4+ T cells generated in μMT−/− mice
are capable of forming memory cells. These quiescent memory cells were also functional, as
they were responsive to the re-challenge infection and underwent expansion (Fig. 2B, left,
shaded bars).
The 2 populations of effector SMARTA CD4 T cells were also transferred to μMT−/− mice.
However, the abundance of the memory SMARTA CD4+ T cells was greatly reduced in the
μMT−/− mice compared to the WT recipients (Fig. 2B, right, white bars), indicating that
both donor cells poorly transitioned to memory in these hosts. Neither donor cell population
responded vigorously upon re-challenge (Fig. 2B, right, shaded bars). These data show that
CD4 memory precursors can form without B cells, however μMT−/− mice fail to sustain
these cells into memory.
Sustained depletion of B cells by anti-CD20 monoclonal antibody
The above data show that despite the early induction of CD4+ T cells that are capable of
becoming memory cells, the long-term survival of CD4 memory was defective in μMT−/−
mice due to the physical loss of memory cells. There are several possible explanations for
the defect in memory in the μMT−/− mice. The μMT−/− mice have a disorganized spleen
structure (63), so there may be a deficiency in stromal cell numbers resulting in low basal
homeostatic cytokines, such as IL-7, that are needed to sustain memory CD4+ T cells.
Alternatively, the μMT−/− mice have defects in critical B cell-derived cytokines that affect
CD4+ T cell survival. To better understand the role of B cells at different stages of CD4
memory formation, we analyzed T cell responses in WT mice that have normal stromal cell
organization but were depleted of B cells by monoclonal anti-CD20 antibody at different
times after infection.
CD20 is expressed on immature B cells, mature B cells, and a subset of memory B cells but
not pro-B cells, plasmablasts, or plasma cells (3, 64). The expression of CD20 has been
reported for unchallenged mice (40, 64), but the expression pattern of molecules can change
dramatically in the context of infection due to the inflammatory environment. We found that
CD20 in the spleen was confined to B cell populations and not induced on T cells,
macrophages, or DC subsets after infection (data not shown). We next evaluated the effect
of anti-CD20 treatment on B cell frequencies in uninfected mice or in mice that were given
LCMV-Armstrong. The depleting monoclonal antibody against CD20 acts by inducing
either FcγR-dependent (ADCC) or complement-mediated lysis of target cells (4, 65). In
uninfected mice, B cells were effectively depleted by anti-CD20, as CD19+B220+ B cell
populations were reduced from 45% to < 0.5% in the spleen and the depletion was
maintained for 45 days (Fig. 3A). A similar loss of CD20+ B cells was also observed (data
not shown). A kinetic analysis of B cell depletion in uninfected mice revealed that the vast
majority of B cells (>98%) were eliminated within 1 week after anti-CD20 was given, and
the depletion lasted 40 days (Fig. 3B). After day 45, the frequency of B cells began to
increase until normal frequencies were observed by day 60. A similar analysis of anti-CD20-
treated mice that were subsequently given LCMV-Armstrong showed that there was a 2-log
decrease in B cell numbers within one week and the B cells remained low in number for 40
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days (Fig. 3C). The anti-CD20 resulted in serum levels of anti-LCMV antibody were at or
below detection at day 40 (Fig. 3D). Thus, anti-CD20 treatment is specific, long-lasting with
a half-life of nearly 1 month, and is unaffected by the inflammation associated with live
infection.
Previously, it was shown that μMT−/− mice and other mice with disrupted splenic
organization have deficient type-1 interferon responses (54). B cells maintain a subcapsular
sinus population of macrophages that are responsive to VSV infection and make protective
amounts of type-1 interferon (56, 57). The early interferon production during LCMV
infection is from pDC and then macrophage populations (54, 55). Therefore, we examined
the B cell-depleted mice for serum levels of IFN and found that they were partially reduced
in the anti-CD20-depleted mice, but not to the extent observed in μMT−/− mice (Fig. 3E).
These results show that even when lymphoid organogenesis unfolds normally, B cells
contribute indirectly to the interferon response.
Vigorous primary T cell response but reduced CD4 memory to acute LCMV infection in the
absence of B cells
The data in Figure 2 indicate that B cells are required after day 7, during the contraction or
memory phases, to sustain CD4 memory. To better understand when B cells are needed,
cohorts of WT mice were treated with anti-CD20 or isotype control antibody at days -14 and
day -7 to remove B cells (Fig. 4A). LCMV-specific Thy1.1+ SMARTA CD4+ T cells were
engrafted into these mice so that we could follow the same population of cells in the
different hosts without the concern of B cell effects on stromal architecture. The engraftment
of the naïve SMARTA CD4+ T cells was not affected by the depletion of B cells when there
was no infection (data not shown). The mice were then infected with LCMV-Armstrong and
the viral load and virus-specific T cell and B cell responses were quantified at 8 days after
infection. This treatment regimen led to a significant loss of B cells at day 8 (Fig. 4B), and
the mice controlled the infection in the liver, lung, and kidney at this time (data not shown).
Consistent with our earlier analyses of endogenous CD4+ T cells, control-treated WT mice,
B cell-depleted mice, and μMT−/− mice generated elevated frequencies of SMARTA CD4+
T cells (Fig. 4C), representing ≥1000-fold expansion of cells in all groups. However, there
was a significant ~2-fold lower number of SMARTA CD4+ T cells in the B cell-depleted
mice compared to B cell-sufficient mice, as observed previously for μMT−/− mice (9). The
proportion of SMARTA CD4+ T cells expressing IFNγ, IL-2, and TNF was unaffected by B
cell-depletion or marginally increased (Fig. 4D, Supplemental Fig. 1A–B & data not
shown), indicating that effector differentiation was not inhibited by the absence of B cells.
Primary virus-specific CD8+ T cell numbers were unaffected by the loss of B cells (Fig.
4E), as observed previously for μMT−/− mice.
Following the peak response, T cells undergo contraction in number and establish a pool of
memory cells. We assessed whether the early depletion of B cells would impact T cell
memory. At day 40 post-infection, the B cell-depleted mice continued to show a 1000-fold
reduction in B cell number compared to isotype-treated mice (Fig. 4F). The immune control-
treated mice contained ~15×104 memory SMARTA CD4+ T cells. However, there was a
reduction in this number to ~5×104 memory CD4+ T cells in the B cell-depleted mice (Fig.
4G), indicating that approximately 2/3rds of CD4 memory requires B cells, even when
lymphoid organogenesis is normal. The number of memory CD4+ T cells in μMT−/− mice
was reduced ~1000-fold compared to the immune control mice, consistent with our earlier
findings concerning endogenous CD4+ T cell responses and the data in Figure 1 (9). The
memory SMARTA CD4+ T cells in B cell-depleted mice showed significant reductions in
the percentage of cells that expressed IFNγ, IFNγ with IL-2, or IFNγ with TNF compared to
cells in control immune mice (Fig. 4H & data not shown). In contrast to CD4 memory
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cells, there was no loss in the number of cytokine+ve CD8+ memory T cells (Fig 4I),
consistent with earlier analyses (9). Thus, B cells are required for most of the memory CD4+
T cell pool and improve the capacity of memory CD4+ T cells to make cytokine. The greater
loss of CD4+ T cell memory in μMT−/− mice suggests that lymphoid architecture plays a
major role in the maintenance of CD4+ T cell memory but not CD8+ T cell memory.
In this same cohort of mice, B cells returned to normal abundance by day 70 (Fig. 4J). At
this time, memory SMARTA CD4+ T cells returned to normal number in the mice that had
been depleted of B cells but not the μMT−/− mice (Fig. 4K). Despite the recovery in B cell
number and the increase in SMARTA cell abundance, memory SMARTA CD4+ T cells
continued to show deficits in cytokine output. For example, the percentage of SMARTA
CD4+ cells that expressed IFNγ with IL-2 remained lower than that observed in isotype-
treated immune mice (Fig. 4L). The per cell amount of IFNγ was reduced; although there
was no significant difference in IL-2 or TNF output between the two groups of mice
(Supplemental Fig. 1C & data not shown). By comparison, the few detectable SMARTA
CD4+ T cells present in the μMT−/− mice showed highly significant reductions in their
ability to produce multiple cytokines and there were major reductions in cytokine output per
cell (Fig. 4L, Supplemental Fig 1C). These data suggest that memory CD4+ T cells
accumulate deficiencies in cytokine production across time when there are no B cells. The
recovery in memory CD4+ T cell frequency that is associated with increases in B cell
number does not rescue memory CD4+ T cell defects in cytokine production.
Throughout these times after infection, virus-specific CD8+ T cells remained at elevated
frequencies without B cells (Fig. 4E, 4I, 4M), and the recovery of B cells did not result in
more memory CD8+ T cells, underscoring the independence of B cells and CD8+ T cell
number. However, there were functional and phenotypic changes in that compartment that
emerged during the memory phase. There were no apparent alterations in cytokine output
early on (Supplemental Fig. 2A–C), but by day 40 there were reductions in the percentage
IFNγ+IL-2+ double positive CD8+ T cells in B cell-depleted mice and in μMT−/− mice and
lower amounts of cytokine made by the memory CD8+ T cells in these mice (Supplemental
Fig. 2D–E). These reductions in cytokine production continued to day 70 when B cell
numbers recovered in the B cell-depleted mice (Supplemental Fig. 2F–G). During the
memory phase, the CD8+CD11ahi population that contains all of the virus-specific memory
CD8+ T cells (66, 67) were evenly distributed between CD8+ T cells with the short-lived
effector cell (SLEC) phenotype and those with the characteristic markers of long-lived
memory cells (MPEC) (68) that express IL-7R (Supplemental Fig. 2H). In contrast, the
majority of memory phenotype CD8+ T cells in the B cell-deficient mice were SLEC. Thus,
stable pools of memory CD8+ T cells form in B cell-depleted mice as observed for μMT−/−
mice (9, 61, 69–71), but the T cells appear activated and show reductions in cytokine
production.
B cell depletion does not diminish established T cell memory
The analyses in above involve mice that were depleted of B cells before infection, but the
duration of B cell-loss continues through the contraction and memory phases of CD4+ T
cells (Fig. 3). To better understand whether B cells function early on or during the
contraction phase or memory maintenance phases, we explored the effect of staggering the
B cell depletion to later times after infection. A cohort of mice containing SMARTA cells
were given acute LCMV. At day 7, the mice were depleted of B cells or not, and the number
and function of memory cells was examined on day 21 (Fig. 5A). At day 21, the control-
treated mice had 2×107 B cells (Fig. 5B) and 6×105 memory SMARTA cells (Fig. 5C). In
contrast, B cell-depleted mice had ~105 B cells and a 2.4-fold reduction of memory CD4+ T
cells (Fig. 5B–C) and these cells were less able to make IFNγ (Fig. 5D). By day 70 the
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number of B cells and memory CD4+ T cells was equivalent to the un-depleted mice (data
not shown). Thus, B cell-depletion initiated during the contraction phase exaggerates the
loss of early memory cells, but the effect is reversed when B cells recover in number.
Another cohort of mice were immunized and allowed to establish T cell memory. During the
memory phase (day 40 post-infection), some of the immune mice were given isotype-control
antibody or anti-CD20 to deplete B cells (Fig. 5E). Two weeks later (day 54), the number of
B cells and memory T cells was quantified. There was a 200-fold reduction in B cells in the
spleen (Fig. 5F); although there remained approximately 105 B cells, some of which are
likely memory B cells, plasmablasts, or germinal center B cells (64, 72, 73). The numbers of
memory SMARTA CD4+ T cells and CD8+ T cells were unaffected by this reduction in B
cells (Fig. 5G & data not shown), although there was a modest reduction in the percentage
of SMARTA CD4+ T cells that could make IFNγ (Fig. 5H). Another set of immune mice
that were allowed to recover B cells and where analyzed at day 210 post-infection also
showed no apparent change in the number or cytokine production of memory T cells
compared those in mice that had B cells the entire time. Thus, B cell-depletion does not
cause major changes in T cell memory once it is established.
Early B cell depletion reduces memory precursor populations
Thus far, the data show that early B cell-depletion before infection or during the contraction
phase reduces the formation of CD4 memory (Fig. 4 & 5). We next examined whether this is
due to a defect in the formation of memory precursor cells. Th1 and TFH-like CD4+ T cells
can form early after infection and represent distinct lineages that develop memory (43–47).
Among the virus-specific CD4+ T cells at day 8, memory precursors are found that re-
express IL-7R and are Ly6Clo and T-bet+ (62). In the infected isotype-control treated mice,
approximately 37% of SMARTA CD4+ T cells were Ly6CloTbet+ (Fig. 6A & B). By
comparison, there was a statistically significant decrease in the proportion of T cells that
were Ly6CloTbet+ in B cell-depleted mice and a greater decrease in the μMT−/− mice (Fig.
6A & B). Thus, the lower level of memory in the B cell-depleted mice is associated with a
reduction in early effector cells with memory potential.
Among the memory precursors within the effector cell population, a subset expresses the
“central memory” phenotypic marker, CCR7, which maintains CD4+ T cells in T cell zones
and is associated with improved homeostatic survival across time (48, 62). About a quarter
of effector SMARTA CD4+ T cells expressed CCR7 in WT mice and in B cell-depleted
mice (Fig. 6C), but this population was greatly reduced in the μMT−/− mice. These data
suggest that memory precursors form at reduced levels without B cells but these cells are
capable of undergoing homeostatic cell division to recover their number when placed in
mice with B cells (Fig. 2) or when B cells return in B cell-depleted mice (Fig. 4).
A number of studies have shown a direct relationship between B cells and the formation of
TFH CD4+ T cells (43–48). Consistent with those studies, far fewer TFH developed in μMT
−/− mice than B cell-sufficient mice (Fig. 6D–E). By comparison, B cell-depleted mice
showed a significant reduction in the number of CXCR5+ICOS+ CD4+ T cells compared to
B cell-sufficient mice, yet there were significantly more TFH in the B cell-depleted mice
than in the μMT−/− mice (Fig. 6D–E). Thus, approximately 1/3 of the TFH response can
occur without B cells when stromal architecture is preserved.
B cell depletion impairs T cell responses to disseminating virus infection and results in
exaggerated weight loss
μMT−/− mice are highly susceptible to disseminating virus infections (9, 74–76). When
confronted with LCMV-Clone13, LCMV-t1b, or LCMV-A22 strains, μMT−/− mice lose
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virus-specific CD4+ T cell responses as well as CD8+ T cell responses, partly through
exaggerated T cell loss and through functional T cell exhaustion. The data above (Fig. 4) for
acute infection show that early B cell-depletion results in an intermediate phenotype where
CD8+ T cells are largely unaffected numerically and CD4 memory is transiently reduced
until B cells recover in number. We next asked whether these effects would impair
immunity to a more aggressive infection. It is well established that CD4+ T cells are
required to sustain CD8+ T cell responses during infections with disseminating strains of
LCMV (17, 19, 22, 23, 77–80). Without T-help, virus-specific CD8+ T cells undergo
deletion or functional exhaustion. We sought to learn whether B cell-depletion affects the
ability of mice to eliminate disseminating LCMV infection. Groups of mice were depleted
of B cells or given isotype-control antibody and then exposed to LCMV-t1b. All mice
showed similar amounts of weight loss during the first week after infection (Fig. 7A).
However, the B cell-sufficient mice recovered weight over the next week. In contrast, μMT
−/− mice showed greater weight loss that was sustained until day 21. The B cell-depleted
mice demonstrated even more weight loss than the infected μMT−/− mice with no evidence
of recovery (Fig. 7A).
The viral load and antiviral T cell responses were evaluated at day 21 post-infection. The B
cell-sufficient mice controlled replicating LCMV-t1b in the serum, liver, lung, and had
reduced levels of virus in the kidneys at day 21 (Fig. 7B). In contrast, B cell-depleted mice
and μMT−/− mice showed several logs increase in viral titers in each of these compartments
(Fig. 7B). The inability of B cell-deficient mice to resolve this disseminating infection
correlated with poor T cell responses. Tetramer+ve (DbGP33-41) CD8+ T cells were present
in all three groups, but there was a greater than 10-fold reduction in tetramer+ CD8+ T cells
in B cell-depleted mice compared to B cell-sufficient mice (Fig. 7C–D, top). Compared to
the B cell-sufficient mice, there was a ~50-fold reduction in the number of CD8+ T cells
capable of making IFNγ in the B cell-deficient mice (Fig. 7C–D, bottom). Tetramer+ve (I-
AbGP67) CD4+ T cells and IFNγ-competent CD4+ T cells were reduced 10–20-fold in the B
cell-depleted mice (Fig. 7E–F). Thus, B cell-depletion severely decreases CD4+ and CD8+
T cell responses through a combination of reduced T cell number and induction of
functional exhaustion, preventing virus control and increasing pathogenesis.
Discussion
Several drugs that deplete B cells are given to treat people with autoimmune disorders.
These therapies are highly tolerated and adverse problems are relatively rare. However,
there is evidence that some individuals develop recurrent infections that depend on cellular
immunity (1, 2). To better understand the role of B cells in the formation of T cell responses,
we compared antiviral T cell responses in B cell-depleted mice, μMT−/− mice, and B cell-
sufficient mice. We show that early T cell differentiation unfolds normally in μMT−/− mice,
but these mice fail to support CD4+ T cell memory. However, effector T cells that form in
the absence of B cells are capable of surviving on into memory when transferred to B cell-
sufficient mice. We evaluated the role of B cells in mice that are not congenitally deficient
in B cells but were depleted early on or during the memory phase of the T cell response after
virus infection. We confirmed that B cells are not needed to generate primary T cell
responses or eliminate acute virus infection. However, eliminating B cells before infection
or during the contraction phase reduced memory CD4 T cell number and cytokine
production, although not to the extent observed in mice that are congenitally deficient in B
cells. Once T cell memory was established, B cell depletion had minimal affect on CD4 or
CD8 memory. There appears to be a direct linkage between the frequency of B cells and
CD4+ T cell memory: when B cells recovered from antibody-mediated depletion, memory
SMARTA cells also increased numerically. We also found that B cells play a key role in
sustaining cellular immunity to a disseminating virus infection. Taken together, the data
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indicate that B cells improve the early establishment & survival of memory T cells
following acute infection and are involved in the vigorous T cell responses that are needed
to eliminate aggressive infections. A prediction based on our study is that B cell depletion
therapies in people who are otherwise immunologically intact will leave their pre-existing T
cell memory intact, but they will form weaker CD4 T cell memory to new antigens and will
be at risk for systemic infections.
A major limitation with using μMT−/− mice is that their spleens do not form properly,
which can potentially impact T cell responses (81). Herein, we circumvented this problem
by following T cell responses in mice that generated spleens with proper microarchitecture.
One caveat to our analyses is that long-term B cell depletion mice may eventually disrupt
some of the existing microarchitecture. For example, there was a gradual loss of marginal
zone cells when B cells were conditionally eliminated by an interferon inducible Cre/Igα-
floxed mouse model (82). Likewise, CD70-transgenic mice gradually loose B cells and
marginal zone structure (82). These long-term changes in lymphoid organization may
impact subsequent cellular immune responses to infection. For example, phagocytic
populations in the marginal zone contribute to sustained interferon production during active
LCMV infection (54, 55) and direct IFN signaling drives T cell differentiation into memory
(83–85). We observed a reduction in type-1 interferon in μMT−/− mice, as reported
previously (54), and a partial reduction in interferon in the B cell-depleted mice (Fig 3E).
The reduction in interferon may be caused by the loss of a macrophage population or pDC in
the spleen following B cell-depletion. Nevertheless, the reduction in type-1 interferon was
not so severe to prevent significant induction of T cell responses and memory as observed in
type-1 interferon-deficient mice. Moreover, delaying the B cell depletion until after the early
inflammatory response (Fig. 5C) showed that B cells increase early CD4 memory.
CD4 memory is reduced when B cells are depleted. We observed that SMARTA CD4+ T
cells were CCR7+ in the B cell-depleted mice (Fig. 6C), and memory CD4+ T cells that are
CCR7+ are thought to have greater proliferative and self-renewing capacity compared to
CCR7− CD4+ T cells (43). In contrast, μMT−/− mice induced CD4+ T cells that were
mostly CCR7− and likely had reduced memory cell potential (43), and the μMT−/− mice
fully loose memory cells with time (Fig. 1). The μMT−/− mice and, to a lesser extent, B
cell-depleted mice generated CD4+ T cells that were shifted to the effector cell phenotype
with enhanced IFNγ, IL-2, and TNF output (Fig 4D and Supplemental Fig. 1B), consistent
with the formation of cells that are intrinsically shorter-lived. Additionally, the B cell-
sufficient environment appears to stimulate intrinsic changes in SMARTA CD4+ T cells that
enable them to undergo a better recall response compared to SMARTA CD4 T cells in μMT
−/− mice (Fig. 2B). Among other potential changes, greater levels of CCR7 expression are
associated with improved recall responses (43, 62). Nevertheless, virus-specific CD4+ T
cells could be affected by regulatory cells. We do not see reductions in the abundance of
Treg cells (CD4+CD25+FoxP3+) in the B cell-deficient mice after LCMV infection (data
not shown), however, it is plausible that regulatory B cells restrain cytokine output by
effector CD4+ T cells, as observed in other models (31, 49, 51, 81).
In addition to influencing the formation of memory cell precursors, B cells contribute to
memory during the contraction phase by sustaining virus-specific CD4+ T cells. CD4+ T
cell memory could be rescued by isolating the T cells from μMT−/− mice and placing them
into B cell-sufficient mice, where they recovered numerically (Fig. 2). This notion is further
supported by the finding that B cell depletion initiated during the contraction phase reduced
the number of memory CD4+ T cells compared to B cell-sufficient mice (Fig. 5C). Thus, B
cells enhance the formation of CD4+ memory precursors and improve their survival during
the contraction phase; however, we do not know which cytokine(s) produced by B cells is
required for these effects. B cells and sustained antigenic stimulation contribute to the
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formation of TFH cells (45, 72, 86, 87). TFH differentiation begins with the expression of
Bcl6 by day 3 after acute LCMV infection (88). Both, TFH and Th1 cells enter the memory
pool and respond to reinfection (44, 62, 89–92). However, memory TFH can respond to
infection in the absence of B cells and remain CXCR5+ up to day 10 post-infection, whereas
naïve CD4+ T cells fail to efficiently form CXCR5+ cells (44). Thus, established TFH
memory cells appear to be less dependent on B cells than primary effector cells. Our
findings are consistent with this, since B cell-depletion during the expansion or contraction
phases reduced CD4 memory, whereas depletion initiated at day 40 (Fig 5G) had minimal
effect on memory. Further studies are needed to determine the temporal requirements of B
cells for the establishment and maintenance of TFH and Th1 memory cells.
B cells eventually recover in mice that had been given anti-CD20 antibody (Fig. 4K) and, at
this time, memory CD4+ T cells repopulate the spleen. It is plausible that memory CD4+ T
cells reside in another niche when B cells are absent but return to the spleen when B cells
recover. Alternatively, we speculate that the recovery of memory T cells could be caused by
enhanced homeostatic cell division due to increased lymphopenia associated cytokines.
Marginal zone cells express, or trans-present, IL-15 that can act on memory T cells and
stimulate their survival (93). Thus, B cell-depletion may reduce monocyte populations or
stromal cell number to deprive T cells of essential survival/maintenance cytokines, such as
IL-7 or IL-15. The return of these sources of homeostatic cytokines may induce memory T
cells to proliferate and accumulate to normal levels.
Chronic virus infections cause significant amounts of morbidity and mortality throughout
the world, and many of the immunological and pathological consequences of chronic
infection can be modeled in mice that are given variants of LCMV that persist over time.
Our data show that B cells improve T cell responses following acute infection and these
positive effects are somewhat more apparent during chronic virus infection, where robust
CD4+ T cell and CD8+ T cell responses need to be sustained to eliminate the infection. The
data in Figure 7 show that B cell-depletion impairs immunity to disseminating virus
infection, implying that B cells directly or indirectly contribute factors that prevent T cell
exhaustion. B cell production of cytokines or antibody may contribute to the resolution of
infection (76, 94, 95). Overall, our findings suggest that B cell-depletion therapies in people
will increase their susceptibility to opportunistic infections. Further studies directed at
understanding how B cells improve cellular immunity may reveal therapeutic approaches to
sustain T cell responses during persisting infections.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Absence of virus-specific CD4+ T cell memory in μMT−/− mice
WT (B6) and B cell-deficient (μMT−/−) mice were given 2×104 SMARTA/Ly5a CD4+ T
cells and then infected with LCMV-Armstrong a few days after engraftment. The T cell
response was analyzed at day 8 (A–B) or day 44 (C–D) after infection by flow cytometry.
(A) At day 8 post-infection, spleen cells were harvested and costained for CD4, Ly5a to
identify the SMARTA CD4+ T cells. The dot plots show examples of surface stained
splenocytes with the SMARTA cells identified within the ovals. The numbers represent their
percentage among all spleen cells. (B) ICCS was used to quantify T cell reactivity to
LCMV-GP61-80 peptide. The dot plots are gated on CD4+ T cells and show donor cell (Ly5a
+) expression of IFNγ. The numbers represent the percentage of CD4+ T cells in each
quadrant. (C) The dot plots show surface staining for CD4 and Ly5a at day 45, with the
SMARTA CD4+ T cells identified within the ovals. (D) The bar graph shows the total
number of splenic SMARTA CD4+ T cells in the two groups of mice. The number above
the white bar indicates the ratio of memory SMARTA cells in WT mice to the number in
BCKO mice. The data represent 2 mice per group from a representative experiment.
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Figure 2. B cells are required during the contraction phase to produce functional memory CD4+
T cells
CD4+ T cells were allowed to differentiate into effector cells and memory precursor cells in
either B cell-sufficient or B cell-deficient (BCKO) mice. The cells were harvested and their
relative survival into the memory phase was compared in the same hosts. (A) An illustration
of the experimental set up. A set of B6 and μMT−/− mice were given 2×104 SMARTA
(Thy1.1+) CD4 T-cells 2 days before the primary infection with LCMV-Armstrong. In
parallel, sets of other infection-matched B6 and μMT−/− mice were generated. At 8 days
post-infection 5×105 SMARTA CD4 T cells from each donor mouse were co-transferred
into the infection-matched B6 or BCKO recipients. Thirty-two days after the co-transfer (40
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days after the primary infection), the recipients were re-challenged with LCMV-Armstrong
(2×106 PFU, i.v.) or left unchallenged. Six days days later, splenocytes were isolated and
surface stained for CD4, Thy1.1, and Ly5a to identify the 2 donor cell populations. (B) The
left graphs show the number of memory Thy1.1+ SMARTA CD4+ T cells (generated in WT
mice) or Ly5a+ SMARTA CD4+ T cells (generated in μMT−/− mice) in the unchallenged
B6 recipients (open bars) or in the challenged B6 recipients (shaded). The right graph shows
the number of memory SMARTA CD4+ T cells in the unchallenged (open bars) or
challenged (shaded) B cell-deficient recipients. The numbers above the bars indicate the fold
expansion of the memory cells upon challenge. The data are pooled from 2 independent
experiments with 6–7 recipient mice/group.
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Figure 3. Anti-CD20 treatment leads to durable loss of B cells followed by cell recovery
Uninfected or infected mice were given 200ug anti-CD20 or isotype control (anti-KLH
IgG2a mAb) into the peritoneal cavity to evaluate the effectiveness and longevity of the B
cell-depletion. (A) The dot plot shows an example of splenocytes surface stained for B cell
markers (B220 and CD19) 28 days after anti-CD20 was given. (B) The line graph shows the
number of CD19+B220+ cells per spleen as measured by flow cytometry at day 0, 7, 28, 40,
49, and 75 post treatment in uninfected mice. The data represent 2 experiments with 3–6
mice/group at each time point. (C) B6 mice were treated with mouse anti-CD20 or isotype
control at fourteen and seven days before infection. The line graph shows the number of
B220+CD19+ cells in the spleen at the indicated days after infection. (D) Mice were
depleted of B cells by two injections of anti-CD20 at day-14 and day-7 before infection. At
the indicated times after infection, sera were collected and the amount of LCMV-specific
IgG was quantified by ELISA. (E) Mice were depleted of B cells at day-7 and then infected
with LCMV. At the indicated times after infection, serum was collected and analyzed for
IFNα levels by ELISA. (B–C) The data represent 2–3 experiments with 3 (day 0 p.i.), 11–13
(day 40 p.i.), and 11–13 (day 70–90 p.i.) mice/group. (D) The data represent 2 experiments
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with 2–6 mice/group at each time point. A two-tailed Student’s t-test was used to evaluate
significance with **P <0.01; ***P <0.001.
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Figure 4. Early B cell depletion transiently reduces CD4 memory but not CD8 memory
(A) An illustration of the experimental approach to assess the effect of early B cell depletion
on a defined population of virus-specific CD4+ T cells. B6 mice were treated with mouse
anti-CD20 mAbs to deplete B cells or isotype control antibody at day-14 & day-7 before
infection. The antibody-treated mice or μMT−/− mice were engrafted with 2×104
SMARTA/Thy1.1+ CD4+ T cells at day -3 and then given LCMV-Armstrong. Spleen cells
were analyzed for the presence of B cells and virus-specific T cells at the indicated times
after infection: day 9 (B–E), day 40 (F–I), day 70 (J–M). (B, F, J) The number of
B220+CD19+ B cells per spleen in mice given anti-CD20 (+) or isotype antibody (−). (C, G,
K) The total number of SMARTA cells per spleen in mice given anti-CD20, or isotype
control, or in μMT−/− (BCKO) mice. (D, H, L) The percentage of SMARTA CD4+ T cells
that were double positive for IFNγ and IL-2 in an ICCS assay. (E, I, M) The number of
CD8+ T cells specific for GP33-41 based on ICCS. The data represent 3 experiments with 6–
13 mice/group. A two-tailed Student’s t-test was used to evaluate significance with *P
<0.05; **P <0.01; ***P <0.001.
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Figure 5. B cell depletion during contraction reduces CD4 memory but pre-existing CD4
memory is unaffected by B cell loss
(A–D) Mice engrafted with 2×103 SMARTA CD4+ T cells were infected with LCMV-
Armstrong. T cells were allowed to differentiate normally until day 7, when the mice were
given anti-CD20 (+) to deplete B cells through the contraction phase or treated with isotype
control (−). Splenocytes were analyzed at day 21. (B) The number of B cells per spleen
based on B220 and CD19 co-staining. (C) The number of SMARTA cells per spleen. (D)
The percentage of SMARTA CD4+ T cells that made IFNγ and IL-2 in an ICCS assay. (E–
H) Naïve mice with 2×103 naïve SMARTA CD4+ T cells were given LCMV-Armstrong
infection and allowed to develop memory. At day 40, some of these immune mice were
given anti-CD20 (+) or isotype-control antibody to evaluate the effect of B cell loss on
existing memory cells. The mice were analyzed 14 days after antibody treatment. (F) The
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number of B cells at day 54. (G) The number of memory SMARTA CD4+ T cells per
spleen. (H). The percentage of SMARTA CD4+ T cells that made IFNγ with IL-2 in an
ICCS assay. The data in B–D represent 7–8 mice per group from one of two experiments.
The data in F–H represent the average of 4 mice per group from one of two similar
experiments. A two-tailed Student’s t-test was used to evaluate significance with *P <0.05;
**P <0.01; ***P <0.001.
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Figure 6. Reduced number of CD4+ memory precursors and TFH cells in mice without B cells
(A) As in Figure 4, WT mice were depleted of B cells (+) or given isotype control antibody
(−) and were engrafted with a small number of SMARTA CD4+ T cells and then infected
with LCMV-Armstrong. μMT−/− mice were similarly engrafted with SMARTA cells
followed by infection. At day 9, the SMARTA CD4+ T cells were identified and analyzed
for T-bet and several surface markers by flow cytometry. (A) The representative dot plots
are gated on the SMARTA cells and show their expression of Ly6C and T-bet. (B) The
percentage of SMARTA CD4+ T cells that are Ly6C-negative and T-bet positive based on
the gating in panels A. (C) The percentage of SMARTA cells that are CCR7-positive. (D)
The percentage of SMARTA cells that co-express CXCR5 and ICOS. (E) The number of
SMARTA CD4+ T cells that were CXCR5+ and ICOS+ per spleen. (A–C) The data
represent 6–8 mice per group in one experiment. (D–E) The data represent the average
(sem) of 6–9 mice per group. A two-tailed Student’s t-test was used to evaluate significance
with *P <0.05; **P <0.01; ***P <0.001.
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Figure 7. B cell depletion diminishes immunity to disseminating LCMV-t1b infection
C57BL/6 mice (with or without αCD20 treatment one week before infection) and μMT−/−
mice were infected intravenously with 2 × 106 PFU of LCMV-t1b. (A) Weight loss during
LCMV-t1b infection (mean±sem with 3–6 mice per group per day). (B) The viral burden in
the mice was measured at day 21 in the serum or indicated tissues. The dotted line indicates
the limit of detection the plaque assay. (C–F) Spleen cells from infected mice were analyzed
on day 21 p.i. by tetramer staining or ICCS. (C) GP33-specific CD8 T cell responses in the
spleen were quantified by tetramer staining (top). The dot plots are gated on CD8+ cells
(top) and show examples of GP33-tetramer positive CD44+ CD8 T cells. The bottom dot
plots are gated on all splenocytes and show CD8 T cell production of IFNγ as measured by
ICCS assay. The numbers indicate the percentage of cells in each region. (D) The bar graphs
show the average (± sem) number of GP33-tetramer positive CD44+ CD8 T cells (top) and
IFN-γ-producing GP33-specific CD8 T cells per spleen in each group of mice. (E) GP61-
specific CD4 T cell responses in the spleen were quantified by tetramer staining (top) or
ICCS (bottom). The upper dot plots are gated on all CD4+ T cells and show examples of
GP61-tetramer positive CD44+ CD4 T cells. The bottom plots are gated on all splenocytes
and show CD4 T cell production of IFNγ. The numbers indicate the percentage of cells in
each region. (F) The bar graphs show the average (± sem) number of GP61-tetramer positive
CD44+ CD4+ T cells (top) and IFN-γ-producing GP61-specific CD4+ T cells (bottom) per
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spleen. For (B–F), the data represent with 3–6 mice/group. Asterisks indicate statistical
significance (*p < 0.05, **p < 0.01, and ***p < 0.001) by a two-tailed Student’s t-test.
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